Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis

Larry W. Moreland, MD
Associate Professor of Medicine; Vice-Chairman for Clinical Research, Department of Medicine; Director, Arthritis Clinical Intervention Program; The University of Alabama at Birmingham; investigator in several clinical trials of etanercept.

Address: Larry W. Moreland, MD, Department of Medicine, The University of Alabama at Birmingham, 068 Spain Rehabilitation Center, 1717 6th Avenue South, Birmingham, AL 35294-7201; larry.moreland@ccc.uab.edu

Larry W. Moreland, MD
Associate Professor of Medicine; Vice-Chairman for Clinical Research, Department of Medicine; Director, Arthritis Clinical Intervention Program; The University of Alabama at Birmingham; investigator in several clinical trials of etanercept.

Address: Larry W. Moreland, MD, Department of Medicine, The University of Alabama at Birmingham, 068 Spain Rehabilitation Center, 1717 6th Avenue South, Birmingham, AL 35294-7201; larry.moreland@ccc.uab.edu

Larry W. Moreland, MD
Associate Professor of Medicine; Vice-Chairman for Clinical Research, Department of Medicine; Director, Arthritis Clinical Intervention Program; The University of Alabama at Birmingham; investigator in several clinical trials of etanercept.

Address: Larry W. Moreland, MD, Department of Medicine, The University of Alabama at Birmingham, 068 Spain Rehabilitation Center, 1717 6th Avenue South, Birmingham, AL 35294-7201; larry.moreland@ccc.uab.edu